Literature DB >> 23532603

High levels of lung resident CD4+CD28null cells in COPD: implications of autoimmunity.

K Hoetzenecker1, A Mitterbauer, E Guenova, T Schweiger, P Altmann, M Zimmermann, H Hofbauer, L Beer, W Klepetko, H J Ankersmit.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a worldwide burden and a major cause of death. Pathogenetic mechanisms underlying the disease are still largely unknown. However, a continuous toxic injury due to tobacco smoking leading to a self-maintaining inflammatory process is considered a key factor in the pathophysiology of the disease. Evidence that autoimmunity might be involved in the maintenance of COPD has been recently noticed with great interest.During the chronic phase of an autoimmune response, lymphocytes lose their costimulatory signals. Previously, CD4+CD28null cells were reported to be systemically heightened in COPD patients. However, a direct role of CD4+CD28null cells in the pathogenesis of COPD is still under discussion, since there is no evidence that CD4+CD28null cells originate from the lungs of diseased patients. Therefore, we evaluated lungs from end-stage COPD patients and compared the levels of tissue infiltrating CD4+CD28null cells to systemic levels. We could show that CD4+CD28null cells are present in high amounts in lung tissue obtained from COPD GOLD IV patients suggesting a direct involvement of those cells in the pathophysiology of COPD. Furthermore, purified lung-resident CD4+ cells showed a stable proliferative response to lung specific elastin and collagen.These results further corroborate the role of autoreactive CD4+ cells in the maintenance of the inflammatory destruction in COPD. Modulating CD4+ cell function might be a new promising tool for future therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23532603     DOI: 10.1007/s00508-013-0340-4

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  19 in total

1.  Hypothesis: does COPD have an autoimmune component?

Authors:  A Agustí; W MacNee; K Donaldson; M Cosio
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

2.  Differential distribution of inflammatory cells in large and small airways in smokers.

Authors:  Salvatore Battaglia; Thais Mauad; Annemarie M van Schadewijk; Antonia M Vignola; Klaus F Rabe; Vincenzo Bellia; Peter J Sterk; Pieter S Hiemstra
Journal:  J Clin Pathol       Date:  2006-08-17       Impact factor: 3.411

3.  Antielastin B-cell and T-cell immunity in patients with chronic obstructive pulmonary disease.

Authors:  Manuela Rinaldi; An Lehouck; Nele Heulens; Renaud Lavend'homme; Vincent Carlier; Jean-Marie Saint-Remy; Marc Decramer; Ghislaine Gayan-Ramirez; Wim Janssens
Journal:  Thorax       Date:  2012-03-22       Impact factor: 9.139

4.  T-cell-mediated lysis of endothelial cells in acute coronary syndromes.

Authors:  Takako Nakajima; Stephanie Schulte; Kenneth J Warrington; Stephen L Kopecky; Robert L Frye; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

5.  Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema.

Authors:  Andrew K Sullivan; Philip L Simonian; Michael T Falta; John D Mitchell; Gregory P Cosgrove; Kevin K Brown; Brian L Kotzin; Norbert F Voelkel; Andrew P Fontenot
Journal:  Am J Respir Crit Care Med       Date:  2005-06-03       Impact factor: 21.405

6.  Increased serum levels of HSP27 as a marker for incipient chronic obstructive pulmonary disease in young smokers.

Authors:  Hendrik Jan Ankersmit; Stefanie Nickl; Eva Hoeltl; Michael Toepker; Christopher Lambers; Andreas Mitterbauer; Benedikt Kortuem; Matthias Zimmermann; Bernhard Moser; Christine Bekos; Barbara Steinlechner; Helmut Hofbauer; Walter Klepetko; Peter Schenk; Balazs Dome
Journal:  Respiration       Date:  2012       Impact factor: 3.580

7.  Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction.

Authors:  Stefan Hacker; Christopher Lambers; Konrad Hoetzenecker; Andreas Pollreisz; Clemens Aigner; Michael Lichtenauer; Andreas Mangold; Tina Niederpold; Matthias Zimmermann; Shahrokh Taghavi; Walter Klepetko; Hendrik Jan Ankersmit
Journal:  Clin Lab       Date:  2009       Impact factor: 1.138

8.  Antielastin autoimmunity in tobacco smoking-induced emphysema.

Authors:  Seung-Hyo Lee; Sangeeta Goswami; Ariel Grudo; Li-Zhen Song; Venkata Bandi; Sheila Goodnight-White; Linda Green; Joan Hacken-Bitar; Joseph Huh; Faisal Bakaeen; Harvey O Coxson; Sebastian Cogswell; Claudine Storness-Bliss; David B Corry; Farrah Kheradmand
Journal:  Nat Med       Date:  2007-04-22       Impact factor: 53.440

9.  Autoantibodies in patients with chronic obstructive pulmonary disease.

Authors:  Carol A Feghali-Bostwick; Aneal S Gadgil; Leo E Otterbein; Joseph M Pilewski; Michael W Stoner; Eva Csizmadia; Yingze Zhang; Frank C Sciurba; Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2007-11-01       Impact factor: 21.405

10.  Identification and clinical association of anti-cytokeratin 18 autoantibody in COPD.

Authors:  Yung-Bin Kuo; C Allen Chang; Yao-Kuang Wu; Meng-Jer Hsieh; Chung-Hsien Tsai; Kuei-Tien Chen; Chun-Yu Chen; Err-Cheng Chan
Journal:  Immunol Lett       Date:  2009-12-28       Impact factor: 3.685

View more
  1 in total

1.  Intracellular secretory leukoprotease inhibitor modulates inositol 1,4,5-triphosphate generation and exerts an anti-inflammatory effect on neutrophils of individuals with cystic fibrosis and chronic obstructive pulmonary disease.

Authors:  Emer P Reeves; Nessa Banville; Dorothy M Ryan; Niamh O'Reilly; David A Bergin; Kerstin Pohl; Kevin Molloy; Oliver J McElvaney; Khalifah Alsaleh; Ahmed Aljorfi; Osama Kandalaft; Eimear O'Flynn; Patrick Geraghty; Shane J O'Neill; Noel G McElvaney
Journal:  Biomed Res Int       Date:  2013-08-29       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.